Peptide-metal nanohybrids (PMN): Promising entities for combating neurological maladies

Nanotherapeutics are gaining traction in the modern scenario because of their unique and distinct properties which separate them from macro materials. Among the nanoparticles, metal NPs (MNPs) have gained importance due to their distinct physicochemical and biological characteristics. Peptides also exhibit several important functions in humans. Different peptides have received approval as pharmaceuticals, and clinical trials have been commenced for several peptides. Peptides are also used as targeting ligands. Considering all the advantages offered by these two entities, the conjugation of MNPs with peptides has emerged as a potential strategy for achieving successful targeting, diagnosis, and therapy of various neurological pathologies.

Automated summary

Nanotherapeutics are gaining popularity for their unique properties compared to macro materials. Metal nanoparticles (MNPs) have emerged as important due to their distinct physicochemical and biological characteristics. Peptides have various important functions in the human body and have been approved as pharmaceuticals, with clinical trials underway. Combining MNPs with peptides has potential for successful targeting, diagnosis, and therapy of neurological pathologies.